Navidea lands $60m for Lymphoseek

Navidea Biopharmaceuticals a term loan of up to $60 million to help it retire debt and promote its Lymphoseek cancer imaging agent.

Navidea (NYSE:NAVB) is getting a loan of up to $60 million it plans to use to retire debt and spur wider use of its Lymphoseek cancer imaging agent.

CRG, Navidea Biopharmaceuticals

News Well, Funding Roundup, Imaging, Oncology

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1QLQwlg